prifetrastat in combination with fulvestrant for neoplasm metastasis

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Trial registered. A trial in people is registered. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 14 Jan 2026: Trial registered, NCT07340619

The trials

NCT07340619: Clinical Trial Evaluating the Biological Activity of a New Drug Identified as Prifetrastat (PF-07248144), Combined With Fulvestrant for the Treatment of Patients With Hormone Receptor Positive (HR+) and HER2 Negative (HER2-) Breast Cancer Extended to Other Organs.

State
Not started
Phase
Phase 2
People
51 planned
Started
18 Sep 2026
Primary completion
18 Nov 2028
Arms
Cohort 2 : prifetrastat incombination with fulvestrant
Results
None posted
  1. 14 Jan 2026: Trial registered

How the status changed

  1. 19 Nov 2026: First set: Trial registered

About the treatment

Kind of treatment: Drug.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.